Shailesh Bondarde

852 total citations
25 papers, 237 citations indexed

About

Shailesh Bondarde is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shailesh Bondarde has authored 25 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shailesh Bondarde's work include Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Shailesh Bondarde is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Shailesh Bondarde collaborates with scholars based in India, United States and United Kingdom. Shailesh Bondarde's co-authors include Minish Jain, Virginia Kaklamani, William J. Gradishar, Nathalie A. Lokker, Sunhee Ro, Vinod Raina, Lee S. Schwartzberg, D. Lokanatha, Tarini Prasad Sahoo and Dinesh Doval and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

Shailesh Bondarde

23 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shailesh Bondarde India 8 152 74 71 56 15 25 237
Ilaria Depetris Italy 7 119 0.8× 42 0.6× 45 0.6× 38 0.7× 8 0.5× 10 194
Carmen Barile Italy 8 204 1.3× 76 1.0× 65 0.9× 86 1.5× 8 0.5× 14 273
Silvana Acquafredda Italy 6 159 1.0× 94 1.3× 42 0.6× 40 0.7× 20 1.3× 8 237
László Landherr Hungary 8 122 0.8× 62 0.8× 42 0.6× 61 1.1× 13 0.9× 20 191
Ajit Desai United States 5 101 0.7× 51 0.7× 44 0.6× 131 2.3× 10 0.7× 10 245
Saya Jacob United States 11 226 1.5× 116 1.6× 89 1.3× 136 2.4× 9 0.6× 27 363
Carlos Mayo United States 9 164 1.1× 151 2.0× 75 1.1× 41 0.7× 12 0.8× 16 254
Simonetta Chiara Stani Italy 11 174 1.1× 136 1.8× 39 0.5× 71 1.3× 39 2.6× 23 316
Konstantinos Rounis Greece 11 228 1.5× 100 1.4× 82 1.2× 75 1.3× 21 1.4× 24 341
K. Kittel Germany 7 180 1.2× 77 1.0× 38 0.5× 142 2.5× 9 0.6× 12 243

Countries citing papers authored by Shailesh Bondarde

Since Specialization
Citations

This map shows the geographic impact of Shailesh Bondarde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shailesh Bondarde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shailesh Bondarde more than expected).

Fields of papers citing papers by Shailesh Bondarde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shailesh Bondarde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shailesh Bondarde. The network helps show where Shailesh Bondarde may publish in the future.

Co-authorship network of co-authors of Shailesh Bondarde

This figure shows the co-authorship network connecting the top 25 collaborators of Shailesh Bondarde. A scholar is included among the top collaborators of Shailesh Bondarde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shailesh Bondarde. Shailesh Bondarde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kumar, Lalit, Sameer Melinkeri, Prasanth Ganesan, et al.. (2023). Daratumumab in Indian Patients with Relapsed and Refractory Multiple Myeloma: A Prospective, Multicenter, Phase IV Study. Future Oncology. 20(4). 191–205.
2.
Gupta, Sudeep, Ghanashyam Biswas, Suresh Babu, et al.. (2021). Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study. The Breast. 60. 147–154. 1 indexed citations
3.
Prabhash, Kumar, Sewanti Limaye, Ullas Batra, et al.. (2021). Treatment of advanced non-small-cell lung cancer. Cancer Research Statistics and Treatment. 4(2). 279–314. 27 indexed citations
4.
Lenz, Heinz‐Josef, Philip Philip, Mark Saunders, et al.. (2017). Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 80(6). 1161–1169. 7 indexed citations
5.
Parikh, Purvish M., Prashant Mehta, Amit Verma, et al.. (2017). Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care. 2(2). 47–47. 2 indexed citations
6.
Prabhash, Kumar, Purvish M. Parikh, Vanita Noronha, et al.. (2017). EGFR testing scenario across 111 centres in India: A questionnaire-based survey.. Journal of Clinical Oncology. 35(15_suppl). e13111–e13111. 4 indexed citations
7.
Bondarde, Shailesh, et al.. (2015). Study of Risk Factors and Clinical Profile of Stroke in Young Adults. 2(1). 15–15. 4 indexed citations
8.
Babu, K Govind, Shailesh Bondarde, Ghanashyam Biswas, et al.. (2015). Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel.. Journal of Clinical Oncology. 33(3_suppl). 302–302. 11 indexed citations
9.
Prabhash, Kumar, Purvish M. Parikh, Vanita Noronha, et al.. (2015). Patterns of EGFR testing for lung cancer among tertiary care centers in India.. Journal of Clinical Oncology. 33(15_suppl). e19114–e19114. 2 indexed citations
10.
Malhotra, Hemant, et al.. (2015). Phase II study of metronomic cyclophosphamide and temozolomide in platinum resistance ovarian cancer.. Journal of Clinical Oncology. 33(15_suppl). e16575–e16575. 3 indexed citations
11.
12.
Jain, Minish, et al.. (2013). Phase I study of weekly treatment with paclitaxel injection concentrate for nanodispersion (PICN), a novel solvent and protein-free formulation of paclitaxel.. Journal of Clinical Oncology. 31(15_suppl). 3039–3039. 1 indexed citations
13.
Jain, Minish, et al.. (2013). Pharmacologic differences in taxanes leading to difference in clinical activity and toxicity.. Journal of Clinical Oncology. 31(15_suppl). e13567–e13567.
14.
Gradishar, William J., Virginia Kaklamani, Tarini Prasad Sahoo, et al.. (2012). A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. European Journal of Cancer. 49(2). 312–322. 66 indexed citations
15.
Jain, Minish, et al.. (2011). Phase I, PK, dose-finding, active controlled study of paclitaxel injection concentrate for nanodispersion (PICN) in subjects with metastatic breast cancer.. Journal of Clinical Oncology. 29(15_suppl). e11585–e11585. 2 indexed citations
16.
Bradley, E C, Richard S. Levy, Dinesh Doval, et al.. (2010). Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 3025–3025. 33 indexed citations
17.
Bondarde, Shailesh, et al.. (2010). Phase II study evaluating safety and efficacy of coadministering propranolol and etodolac for treating cancer cachexia.. Journal of Clinical Oncology. 28(15_suppl). e18059–e18059. 6 indexed citations
18.
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilaria Depetris Breakdown of academic impact, for papers by Carmen Barile Breakdown of academic impact, for papers by Silvana Acquafredda Breakdown of academic impact, for papers by László Landherr Breakdown of academic impact, for papers by Ajit Desai Breakdown of academic impact, for papers by Saya Jacob Breakdown of academic impact, for papers by Carlos Mayo Breakdown of academic impact, for papers by Simonetta Chiara Stani Breakdown of academic impact, for papers by Konstantinos Rounis Breakdown of academic impact, for papers by K. Kittel
Rankless by CCL
2026